Figure 7: AZD1480 inhibits STAT3/STAT5B-mutant transduced NK cells.

STAT3-mutant (a) or STAT5B mutant (b) transduced, GFP⁺-sorted KAI3 cells were treated with 0.5 μM AZD1480 for 72 h. Viable cell number was determined using Vi-cell XR cell viability analyser (Beckman Coulter Inc.) as described in Supplementary Methods and normalized to the corresponding untreated sample. Means±s.d. of two biological replicates are shown. (c) Normalized viable cell number of STAT5B-WT (left) or N642H-mutant (right) transduced KAI3 cells treated with progressively increasing doses of AZD1480 for 72 h. Each column represents mean±s.d. of three biological replicates. (d) P-STAT5 (Y699) levels were analysed by western blot on EV, STAT5B-WT, N642H or I704L transduced KAI3 cells treated with progressively increasing doses (0.5 μM, 1 or 2 μM) of AZD1480 for 4 h (e) Normalized numbers of viable STAT3-mutated NKYS and YT cells treated as in (c) are shown *P<0.01 versus no treatment; **P<0.05 versus no treatment; Student’s t-test. NS: not significant.